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BRIEF REPORTAn Examination of Adults on Antipsychotic Medication at Risk for
Metabolic Syndrome: A Comparison with Obese and Eating
Disorder Populations
Colleen Stiles-Shields*, Cynthia Bogue, Daniel Le Grange & Daniel Yohanna
Department of Psychiatry and Behavioral Neuroscience, The University of Chicago, Chicago, IL, USAAbstractLittle research has explored how eating disorders (ED) may be involved in the increased risk for metabolic syndrome in adults on
antipsychotic medication. This pilot study compared participants on antipsychotic medication with obese and ED samples with respect
to demographic and psychosocial factors. Participants (antipsychotic medication n= 12; obese n= 12; ED n= 12), were adults presenting
to an outpatient psychiatry department (83.3% women; M age = 45.75 11.5). Analysis of variance, analysis of covariance and chi-square
tests were used to compare the samples. Participants on antipsychotic medications had a signiﬁcantly lower mean body mass index than
the obese (p< .001) and ED (p< .05) samples, as well as signiﬁcantly lower Restraint Total scores (p< .05) and subjective binge episode
frequency (p< .05) than the ED sample. The lack of signiﬁcant differences that occurred between the antipsychotic medication sample
and two eating disorder samples signiﬁcantly different from one another indicates that this population may have unique symptomology
and treatment needs. Copyright © 2012 John Wiley & Sons, Ltd and Eating Disorders Association.Keywords
antipsychotic medication; metabolic syndrome; obesity; binge eating
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symptoms of metabolic syndrome (ADA, APA,, & AACE, 2004;
Gothefors, Adolfsson, & Attval, 2010; Khazaal, Billieux, & Fresard,
2009; Meyer & Stahl, 2009; Narang, Mostafa, & Parlapalli, 2010;
Remington, 2006). Metabolic syndrome is deﬁned by the presence
of at least three of the following conditions: blood pressure greater
than 130/85mmHg, serum triglycerides level of greater than
150mg/dL, serum glucose level of greater than 110mg/dL, waist
circumference greater than 102 cm in men and 88 cm in women,
and high-density lipoprotein cholesterol level of less than 40mg/dL in
men and 50mg/dL in women; having a bodymass index (BMI) over
25 (i.e. being overweight or obese) is also an associated risk factor
(Ford, Giles, & Dietz, 2002). Metabolic syndrome is of concern as
its symptoms indicate increased risk for conditions such as
cardiovascular disease, type II diabetes mellitus and a decreased life
expectancy (Grundy et al., 2005).
Weight gain and obesity are prevalent in populations taking
second generation antipsychotic medication (Khazaal et al.,
2009; Malhotra et al., 2012; Remington, 2006). Perhaps for this
reason, other factors, such as symptoms of eating disorders
(ED), have not been explored in relation to this population’s
increased risk for metabolic syndrome. Outside of attempts to
use antipsychotic medications as a means of weight gain in
patients with anorexia nervosa (McKnight & Park, 2010;Eur. Eat. Disorders Rev. 21 (2013) 165–169 © 2012 John Wiley & Sons, Ltd and Eating DisorderMehler-Wex, Romanos, Krirchheiner, & Schulze, 2008), limited
research is available to identify ED comorbidity within this popu-
lation (Miotto, Pollini, & Restaneo, 2010). Initial ﬁndings indicate
that over half of patients with schizophrenia and a BMI greater
than or equal to 28 exhibit binge eating symptomology (Khazaal,
Fresard, & Borgeat, 2006) and that disordered eating is higher in a
sample of Egyptian adults with schizophrenia than controls
(Fawzi & Fawzi, 2012). Additionally, clozapine and olanzapine
have been indicated to increase risk of ED symptomology (Bromel,
Blum, & Ziegler, 1998; Gebhardt, Haberhausen, & Krieg, 2007). It
is important to identify the health behaviours and possible ED
symptomology of this population so that effective interventions
can be developed.
The purpose of the current study is to compare demographic,
psychosocial and ED variables of a pilot sample of adults on anti-
psychotic medication at risk for metabolic syndrome to similarly
aged, treatment-seeking samples of obese adults and adults with
diagnoses of eating disorder not otherwise speciﬁed, binge eating
disorder subtype (EDNOS-BED). Consistent with previous
ﬁndings that both ED symptoms and obesity are present in sam-
ples of adults on antipsychotic medication (Khazaal et al., 2009;
Remington, 2006), we hypothesized that the sample on antipsy-
chotic medication would not signiﬁcantly differ from the obese
or EDNOS-BED samples in terms of BMI or ED symptoms.165s Association.
Table 1 Demographic and health information of sample of adults on
antipsychotic medication
Measure
Mean SD
Age (years) 49.75 10.99
BMI 32.95 5.39
BMR 1603 180.7
Waist circumference 40.94 5.63
(inches)
Glucose 98.08 16.49
(60–109mg/dL)
Cholesterol 172.67 36.77
(120–199mg/dL)
HDL Cholesterol 58.58 19.80
(40–80mg/dL)
Triglycerides 97.58 30.75
(30–149mg/dL)
LDL Cholesterol 94.58 32.97
(60–129mg/dL)
n %
Gender
Male 2 16.7
Female 10 88.3
Ethnicity
Caucasian 2 16.7
Minority 10 88.3
Activity level
Low 5 41.7
Light 2 16.7
Moderate 4 33.3
High 1 8.3
Note: BMI, body mass index; BMR, basal metabolic rate; mg/dL, milligrams per
deciliter; HDL, High-density lipoprotein; LDL, low-density lipoprotein.
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Participants
Participants were adults (n= 36), aged 24 to 66 years (M age =
45.75 11.5 years), presenting for an initial ED evaluation at
The University of Chicago Medicine’s Eating Disorders Program
or for a Healthy Eating and Activity Learning (HEAL) education
curriculum at the University of Chicago Medicine’s Department
of Psychiatry and Behavioral Neuroscience. Participants had
a mean BMI of 40.6 9.3 and composed of mostly women
(83.3%; n= 30), Caucasians (44.4%; n= 16) and African
Americans (44.4%; n= 16). Twelve participants met the criteria
of Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition, Text Revision (DSM-IV TR; American Psychiatric
Association, 2000) for EDNOS-BED; 12 participants were obese
(BMI> 30) and did not meet any DSM-IV TR criteria for
an ED; 12 participants were patients of the University of
Chicago Medicine’s Department of Psychiatry and Behavioral
Neuroscience on antipsychotic medication and at risk for
metabolic syndrome that participated in the HEAL programme.
The 12 participants on antipsychotic medication had diagnoses
of Bipolar Disorder Not Elsewhere Classiﬁed, Chronic Paranoid
Schizophrenia, Chronic Schizo-Affective Disorder, Paranoid
Schizophrenia and Unspeciﬁed Schizophrenia; this sample was
also prescribed at least one of the following medications at
assessment: Aripirazole, Clozapine, Haloperidol, Fluphenazine,
Risperidone, Clorpromazine, Perphenazine and Olanzapine.
Procedure
Participants completed questionnaires during a baseline assessment.
All data were collected before the start of treatment.Written informed
consent for patients over 18 years of age was obtained. This study
was approved by The University of Chicago’s Institutional Review
Board.
Physical assessment
Participants’ weight and height were measured by a trained
research assistant or licensed nurse using a calibrated digital or
balance-beam scale and stadiometer. All patients were weighed
in light, indoor clothing.
Measures
The Eating Disorder Examination Questionnaire (EDE-Q; Fairburn
& Beglin, 1994) is a self-report questionnaire that assesses the
cognitive and behavioural symptoms of EDs. Cognitive symptoms
of EDs (e.g. fear of weight gain, overevaluation of shape and
weight) are assessed for the past 28 days using a 7-point Likert
scale, with higher scores indicating more severe eating-related
psychopathology. Global scores reﬂect the overall severity of ED
symptoms, including dietary restraint, eating concerns, shape con-
cerns and weight concerns. Frequency of self-induced vomiting,
laxative misuse, diuretic misuse, driven exercise, fasting,
objective binge eating (OBE; eating episodes involving the con-
sumption of an objectively large amount of food accompanied
by a sense of loss of control), subjective binge eating (SBE; eating
episodes involving an amount of food that is not objectively
large but is considered excessive by the respondent, accompanied166 Eur. Eat. Disordersby a sense of loss of control) and objective overeating
episodes (OOE; eating episodes involving the consumption of an
objectively large amount of food without the sense of loss of con-
trol) is assessed for 1month prior to assessment. EDE-Q scores
have demonstrated high test–retest reliability (Luce & Crowther,
1999; Reas, Grilo, & Masheb, 2006), and the subscale scores
on the EDE-Q have demonstrated good internal consistency
(Peterson et al., 2007).
The Beck Depression Inventory I (BDI; Beck, 1987) is a 21-item
self-report questionnaire designed to assess depressive symptoms.
Scores range from 0 to 63, with scores over 18 indicating
moderate to severe depressive symptoms. The BDI has good psy-
chometric properties (Barrera & Garrison-Jones, 1988; Kashani,
Sherman, Parker, & Reid, 1990) and has been utilized in multiple
studies of samples with (Jackson, Grilo, & Masheb, 2000; Lock
et al., 2010; Zaitsoff, Celio Doyle, Hoste, & le Grange, 2008) and
without (Niendam et al., 2006; Weeks & Heimberg, 2005) EDs.Data analysis
Analysis of variance and chi-square analyses were used to
compare participants on antipsychotic medication, participantsRev. 21 (2013) 165–169 © 2012 John Wiley & Sons, Ltd and Eating Disorders Association.
C. Stiles-Shields et al. Antipsychotic Medication & Metabolic Syndromewith EDNOS-BED and obese participants on basic demographic
features. Analyses of covariance (ANCOVAs), controlling for
ethnicity, race and BMI were used to compare participants on
antipsychotic medication with participants having EDNOS-BED
on continuous measures of eating-related and general psychopa-
thology. ANCOVAs, controlling for ethnicity and BMI were used
to compare participants on antipsychotic medication with obese
participants on continuous measures of eating-related and general
psychopathology. We considered including other covariates as well,
such as race; however, none of these variables signiﬁcantly contrib-
uted to the models and were therefore removed from the analyses.
Comparisons of the EDNOS-BED and obese samples also occurred
in order to conﬁrm that, consistent with previous ﬁndings
(Mussell et al., 1996; Specker, de Zwaan, Raymond, & Mitchell,
1994), signiﬁcant differences exist between the two comparison
groups. ANCOVAs, controlling for BMI, were used to compare
participants with EDNOS-BED and obese participants on continu-
ous measures of eating-related and general psychopathology.
Results
The 12 participants on antipsychotic medication at risk for
metabolic syndrome were mainly women (88.36%; n= 10;
Table 1) and minorities (88.36%; n= 10). The majority were
obese (M BMI = 32.95 5.4) and engaged in low activity
levels (i.e. little to no exercise; 41.7%; n= 5). Participants also
endorsed OOEs (M frequency= 3.45 6.6), OBEs (M frequency=
2.27 6.0), SBEs (M frequency= 1.64 1.9), self-induced vomit-
ing (M frequency= 1.27 4.2), and driven exercise (M frequency=
3.20 9.4) in the 28days prior to assessment. The participants
on antipsychotic medication had signiﬁcantly lower averageTable 2 Distribution of demographic and psychosocial variables by group
Variables
Sample on antipsychotic medication Overw
(n= 12)
Mean SD
Age (years) 49.75 10.99
BMI 32.95 5.39
Race (n %)
Caucasian 2 16.7 6
Minority 10 88.3 6
BDI total score 14.64 9.06
EDE-Q weight concern total 2.53 1.64
EDE-Q shape concern total 3.38 1.92
EDE-Q restraint total 1.05 1.20
EDE-Q eating concern total 1.96 1.44
EDE-Q global score 2.23 1.36
OOE 3.45 6.55
OBE 2.27 5.95
SBE 1.64 1.91
Self-induced vomiting 1.27 4.22
Laxative misuse 0
Driven exercise 3.20 9.44
Note: EDNOS, eating disorder not otherwise speciﬁed; BMI, body mass index; BDI, Beck
objective overeating episode; OBE, objective bulimic episode; SBE, subjective bulimic ep
Eur. Eat. Disorders Rev. 21 (2013) 165–169 © 2012 John Wiley & Sons, Ltd and Eating DisorderBMIs than the obese sample (p< .001) and the EDNOS-BED
sample (p< .05). Signiﬁcant differences in ethnicity were also
present between the antipsychotic medication sample and the
obese sample (p< .05) and the EDNOS-BED sample (p< .05).
Comparison of antipsychotic medication and
eating disorder not otherwise speciﬁed, binge
eating disorder subtype samples
The EDNOS-BED sample had signiﬁcantly higher Restraint Total
scores [F(4, 22) = 3.40; p< .05; Table 2] and frequency of SBEs in
the 28 days prior to assessment [F(4, 19) = 4.21; p< .05] than the
antipsychotic medication sample. No other signiﬁcant differences
were present. The EDNOS-BED sample denied any occurrence of
self-induced vomiting, whereas participants on antipsychotic
medication endorsed this compensatory behaviour and denied
any laxative misuse.
Comparison of antipsychotic medication and
obese samples
No signiﬁcant differences were present between the antipsy-
chotic medication and the obese samples. The obese sample
denied any occurrence of self-induced vomiting or driven
exercise, whereas participants on antipsychotic medication en-
dorsed both compensatory behaviours and denied any laxative
misuse.
Comparison of eating disorder not otherwise
speciﬁed, binge eating disorder subtype and
obese samples
The EDNOS-BED sample had signiﬁcantly higher Eating Concern
Total scores [F(2, 23) = 3.53; p< .05], Shape Concern Total scoreseight and obese sample EDNOS sample
Test statistic(n= 12) (n= 12)
Mean SD Mean SD
45.67 12.87 41.83 9.88 F(2, 35) = 1.47; p= .25
49.28 5.60 39.70 8.32 F(2, 35) = 18.70; p= .000
50.0 8 66.7 w2(2, N= 36) = 6.3; p= .043
50.0 4 33.3
11.33 5.94 18.83 9.10 F(4, 34) = 1.26; p= .308
2.70 1.06 3.90 1.31 F(4, 34) = 2.77; p= .045
3.04 1.21 4.44 1.15 F(4, 34) = 2.90; p= .038
1.93 1.9 3.05 1.42 F(4, 34) = 3.66; p= .015
1.17 1.21 2.65 1.54 F(4, 34) = 1.99; p= .122
2.21 0.98 3.51 1.10 F(4, 34) = 3.18; p= .027
3.60 4.53 8.08 8.64 F(4, 32) = 2.84; p= .043
2.73 4.41 8.73 7.74 F(4, 32) = 3.22; p= .024
1.18 2.71 4.78 5.93 F(4, 30) = 4.03; p= .011
0 0 F(4, 30) = 0.48; p= .750
0.70 2.21 0.78 2.33 F(4, 30) = 0.97; p= .440
0 1.22 2.44 F(4, 27) = 1.27; p= .312
Depression Inventory; EDE-Q, Eating Disorders Examination Questionnaire; OOE,
isode.
167s Association.
Antipsychotic Medication & Metabolic Syndrome C. Stiles-Shields et al.[F(2, 23) = 4.01; p< .05], EDE-Q Global scores [F(2, 23) = 4.48;
p< .05], as well as higher frequencies of OOEs [F(2, 21) = 7.19;
p< .01], OBEs [F(2, 21) = 8.37; p< .01], and SBEs [F(2,
19) = 6.58; p< .01].
Discussion
The purpose of this study was to examine the demographic,
psychosocial and ED symptomology of a sample of adults on
antipsychotic medication at risk for metabolic syndrome and
to compare this group to similarly aged, treatment-seeking
samples of obese adults and adults with diagnoses of
EDNOS-BED. Consistent with our hypothesis, there were very
few signiﬁcant differences between the antipsychotic medication
sample and the EDNOS-BED and obese samples in psychosocial
and ED symptomology. However, the antipsychotic medication
sample had signiﬁcantly lower BMIs than both the obese
and the EDNOS-BED groups. Additionally, the EDNOS-BED
groups had signiﬁcantly higher Restraint Total scores and SBE
frequencies.
The lower BMIs of the participants on antipsychotic medica-
tion are likely due to the fact that the sample was recruited for
being at risk for symptoms of metabolic syndrome. Therefore
those with BMIs below 30 (i.e. overweight or normal weight) were
not excluded from the sample. The lower Restraint Total scores
and frequencies of SBEs compared with the EDNOS-BED group
may indicate that, as this sample was not actively engaged in168 Eur. Eat. Disordersweight loss activities or self-identify as having EDs, they are less
likely to experience distress in regards to their ability to limit their
food consumption or experience loss of control during an episode
of eating that does not involve consuming an objectively large
amount of food.
To our knowledge, this is the ﬁrst study to examine an adult,
American sample on antipsychotic medication at risk for meta-
bolic syndrome in demographic, psychosocial and ED symp-
toms. Understanding the differences and similarities this
population has to obese and ED samples provides insights into
prevention and treatment interventions for the many serious
health sequelae of metabolic syndrome. There were several
strengths to this analysis, speciﬁcally diverse samples assessed
with well-validated measures. Yet limitations also warrant ac-
knowledgment. Our sample sizes were quite limited; future
studies should explore the characteristics of this population with
larger samples.
In summary, consistent with previous ﬁndings (Mussell et al.,
1996; Specker et al., 1994), the obese and EDNOS-BED samples
were signiﬁcantly different in many variables of ED severity, yet
the antipsychotic medication sample had very few signiﬁcant
differences from either group. Our ﬁndings indicate that adults
on antipsychotic medication at risk for metabolic syndrome
comprise a unique population. Future research should examine
psychosocial variables and ED symptomology with larger samples
to identify effective prevention and treatment interventions for
this population.REFERENCES
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